Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02447003
What this trial is testing

Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)

Who this might be right for
Breast Cancer
Merck Sharp & Dohme LLC 254
Large-scale testing (Phase 3)Study completedNCT02252042
What this trial is testing

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Who this might be right for
Head and Neck Squamous Cell Cancer
Merck Sharp & Dohme LLC 495
Large-scale testing (Phase 3)Not Yet RecruitingNCT07238569
What this trial is testing

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Cancinoma (NPC)Nasopharangeal Cancer
Sun Yat-sen University 516
Early research (Phase 1)Looking for participantsNCT06952010
What this trial is testing

XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

Who this might be right for
Solid TumorAdvanced Solid TumorMetastatic Solid Tumor+1 more
Exelixis 303
Testing effectiveness (Phase 2)Ended earlyNCT03901573
What this trial is testing

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Who this might be right for
MelanomaMerkel Cell CarcinomaCutaneous Squamous Cell Carcinoma
NeoImmuneTech 31
Large-scale testing (Phase 3)Looking for participantsNCT06623422
What this trial is testing

Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 680
Early research (Phase 1)Active Not RecruitingNCT06898957
What this trial is testing

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Who this might be right for
Small Cell Lung Cancer
Amgen 29
Large-scale testing (Phase 3)Active Not RecruitingNCT04534205
What this trial is testing

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

Who this might be right for
Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE 358
Testing effectiveness (Phase 2)Study completedNCT02639065
What this trial is testing

Durvalumab (MEDI4736) in Esophageal Cancer

Who this might be right for
Esophageal Cancer
Shadia Jalal, MD 39
Not applicableActive Not RecruitingNCT05364086
What this trial is testing

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
University of Rochester NCORP Research Base 2,100
Large-scale testing (Phase 3)Not Yet RecruitingNCT07718737
What this trial is testing

Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Multitude Therapeutics Inc. 512
Testing effectiveness (Phase 2)Looking for participantsNCT04107077
What this trial is testing

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

Who this might be right for
Gastric CancerPeritoneal Carcinomatosis
University of Chicago 21
Testing effectiveness (Phase 2)Study completedNCT04819373
What this trial is testing

BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

Who this might be right for
Tumor, Solid
Eikon Therapeutics 1
Not applicableUnknownNCT05819905
What this trial is testing

Radiomics for prEdiction of lunG cAncer biologY

Who this might be right for
Non Small Cell Lung CancerPET/CTPD-L1+1 more
Poitiers University Hospital 600
Large-scale testing (Phase 3)Ended earlyNCT02450331
What this trial is testing

Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

Who this might be right for
Carcinoma, Transitional Cell
Hoffmann-La Roche 809
Very early researchStudy completedNCT03132467
What this trial is testing

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+14 more
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Looking for participantsNCT03907475
What this trial is testing

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Who this might be right for
Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
National Cancer Institute (NCI) 115
Not applicableLooking for participantsNCT06549907
What this trial is testing

A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy

Who this might be right for
MSS Metastatic Colorectal CancersMSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Peking University Cancer Hospital & Institute 50
Testing effectiveness (Phase 2)Study completedNCT02902029
What this trial is testing

Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Who this might be right for
Malignant Melanoma
University Hospital, Essen 186
Early research (Phase 1)Study completedNCT02013219
What this trial is testing

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 52
Next Page